The SARS-CoV-2 infection was in 2020 responsible for new disease related chronic conditions which have been referred to as Post-COVID. To date it is still unknown how common this condition is and which symptoms are related to it. The aim of the study is to monitor the onset of these conditions in a large observational study consisting of German health insurance data.
SARS-CoV-2 is a virus of the coronavirus family, which includes a large number of viruses that can cause a wide variety of diseases in humans. The SARS-CoV-2 virus causes acute symptoms associated with the infection and can cause chronic conditions known as Post-COVID. To understand the prevalence and variety of Post-COVID a large observational study of health insurance data from Germany was set up. The exposed patients were identified by a diagnosis indicating a confirmed laboratory test for COVID. The basic question concerns the burden of the Post-COVID condition. The study investigate which symptoms are more common in humans after the exposure to the virus compared to a matched unexposed cohort. Further will this be investigated in the subgroup of children and adolescents and those who have been hospitalized due to the virus infection.
Study Type
OBSERVATIONAL
Enrollment
157,134
The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
Center for Evidence-Based Healthcare
Dresden, Saxony, Germany
Incidence of abdominal pain
Incidence of a diagnosis of abdominal pain recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of acute pain
Incidence of a diagnosis of acute pain recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of adjustment disorder
Incidence of a diagnosis of adjustment disorder recorded in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of anuria/oliguria
Incidence of a diagnosis of anuria/oliguria in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of anxiety disorder
Incidence of a diagnosis of anxiety disorder in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of arthritides
Incidence of a diagnosis of arthritides in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of ascites
Incidence of a diagnosis of ascites in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of behavioral symptoms
Incidence of a diagnosis of behavioral symptoms in outpatient or inpatient setting
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of cachexia
Incidence of a diagnosis of cachexia in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of carditis due to viruses
Incidence of a diagnosis of carditis due to viruses in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of changes in bowel habits
Incidence of a diagnosis of changes in bowel habits due to viruses in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of chronic fatigue syndrome
Incidence of a diagnosis of chronic fatigue syndrome in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of cognitive function impairment
Incidence of a diagnosis of cognitive function impairment in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of concentration impairment/concentration deficit
Incidence of a diagnosis of concentration impairment/concentration deficit in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of cough
Incidence of a diagnosis of cough in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of COVID toe
Incidence of a diagnosis of COVID toe in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of depression
Incidence of a diagnosis of depression in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of developmental delay
Incidence of a diagnosis of developmental delay in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of disorientation
Incidence of a diagnosis of disorientation in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of dysgeusia
Incidence of a diagnosis of dysgeusia in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of dyslexia
Incidence of a diagnosis of dyslexia in in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of dysmenorrhea
Incidence of a diagnosis of dysmenorrhea in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of dysphagia
Incidence of a diagnosis of dysphagia in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of dyspnea
Incidence of a diagnosis of dyspnea in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of dysuria
Incidence of a diagnosis of dysuria in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of emotional and behavioral disorder
Incidence of a diagnosis of emotional and behavioral disorder in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of epistaxis
Incidence of a diagnosis of epistaxis in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of eye pain
Incidence of a diagnosis of eye pain in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of facial nerve paralysis
Incidence of a diagnosis of facial nerve paralysis in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of fever
Incidence of a diagnosis of fever in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of flatulence
Incidence of a diagnosis of flatulence in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of gangrene
Incidence of a diagnosis of gangrene in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of general symptoms
Incidence of a diagnosis of general symptoms in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of hair loss
Incidence of a diagnosis of hair loss in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of headache
Incidence of a diagnosis of headache in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of hearing loss/tinnitus
Incidence of a diagnosis of hearing loss/tinnitus in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of heart failure
Incidence of a diagnosis of heart failure in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of heart murmurs
Incidence of a diagnosis of heart murmurs in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of heartburn
Incidence of a diagnosis of heartburn in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of hemorrhage
Incidence of a diagnosis of hemorrhage in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of hepatomegaly and splenomegaly
Incidence of a diagnosis of hepatomegaly and splenomegaly in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of hoarseness
Incidence of a diagnosis of hoarseness in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of hyperhidrosis
Incidence of a diagnosis of hyperhidrosis in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of hypotension
Incidence of a diagnosis of hypotension in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of impaired balance
Incidence of a diagnosis of impaired balance in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of joint pain
Incidence of a diagnosis of joint pain in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of loss of appetite
Incidence of a diagnosis of Loss of appetite in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of lymphadenopathy
Incidence of a diagnosis of lymphadenopathy in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Malaise/fatigue/exhaustion
Incidence of a diagnosis of Malaise/fatigue/exhaustion in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of memory impairment
Incidence of a diagnosis of memory impairment in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of meningismus
Incidence of a diagnosis of meningismus in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of mood disorder
Incidence of a diagnosis of mood disorder in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of movement disorders
Incidence of a diagnosis of movement disorders in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of myalgia
Incidence of a diagnosis of myalgia in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of myocardial infarction
Incidence of a diagnosis of myocardial infarction in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of myocarditis
Incidence of a diagnosis of myocarditis in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of nausea
Incidence of a diagnosis of nausea in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of neurasthenia
Incidence of a diagnosis of neurasthenia in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of neurological manifestation of Post-COVID
Incidence of a diagnosis of Neurological manifestation of Post-COVID in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of obsessive-compulsive disorder
Incidence of a diagnosis of obsessive-compulsive disorder in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of oedema
Incidence of a diagnosis of oedema in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of other cardiac arrhythmias
Incidence of a diagnosis of other cardiac arrhythmias in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of other coordination disorders/ataxia
Incidence of a diagnosis of other coordination disorders/ataxia in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of other symptoms of the urinary system
Incidence of a diagnosis of other symptoms of the urinary system in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of pain, not elsewhere classified
Incidence of a diagnosis of pain, not elsewhere classified in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of paresis
Incidence of a diagnosis of paresis in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of paresthesia of skin
Incidence of a diagnosis of paresthesia of skin in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of pathological findings from male genital tract
Incidence of a diagnosis of pathological findings from male genital tract in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of pathological lung findings
Incidence of a diagnosis of pathological lung findings from male genital tract in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of pathological reflexes
Incidence of a diagnosis of pathological reflexes in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of pericarditis
Incidence of a diagnosis of pericarditis in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of polyuria
Incidence of a diagnosis of polyuria in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of Post-COVID
Incidence of a diagnosis of Post-COVID in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of pulmonary embolism
Incidence of a diagnosis of pulmonary embolism in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of rash
Incidence of a diagnosis of rash in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of respiratory insufficiency
Incidence of a diagnosis of respiratory insufficiency in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of seizures
Incidence of a diagnosis of seizures in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of sensation and perception disorder
Incidence of a diagnosis of sensation and perception disorder in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of shock
Incidence of a diagnosis of shock in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of sinus vein thrombosis
Incidence of a diagnosis of sinus vein thrombosis in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of sleep disorders
Incidence of a diagnosis of sleep disorders in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of somatization disorder
Incidence of a diagnosis of somatization disorder in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of somnolence
Incidence of a diagnosis of somnolence in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of sopor/coma
Incidence of a diagnosis of sopor/coma in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of speech and language disorders
Incidence of a diagnosis of speech and language disorders in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of stroke
Incidence of a diagnosis of stroke in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of subcutaneous nodules
Incidence of a diagnosis of subcutaneous nodules in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of syncope
Incidence of a diagnosis of syncope in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of tetany
Incidence of a diagnosis of tetany in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of throat/chest pain
Incidence of a diagnosis of throat/chest pain in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of thrombosis
Incidence of a diagnosis of thrombosis in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of urethral discharge
Incidence of a diagnosis of urethral discharge in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of urinary retention
Incidence of a diagnosis of urinary retention in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of vertigo
Incidence of a diagnosis of vertigo in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of visual disturbances
Incidence of a diagnosis of visual disturbances in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2
Incidence of weight gain/loss, eating disorders
Incidence of a diagnosis of weight gain/loss, eating disorders in outpatient or inpatient setting
Time frame: At least 12 weeks after the infection by SARS-CoV-2